

1

**Name of Journal:** *World Journal of Hepatology***ESPS Manuscript NO:** 25571**Manuscript Type:** Minireviews

**How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma**

Raoul JL *et al.* When to stop sorafenib in HCC

### Abstract

Sorafenib is thus far the only systemic treatment for hepatocellular carcinoma (HCC) based on the results of two randomized controlled trials performed in Western and in Eastern countries, despite a poor response rate (from 2% to 3.3%) following conventional evaluation criteria. It is now recognized that the criteria (EASL criteria, mRECIST) based on contrast enhanced techniques (CT scan, MRI) aimed to assess the evolution of the viable part of the tumor (hypervascularized on arterial phase) are of

### Match Overview

1

**Internet** 9 words  
crawled on 09-Oct-2015  
[www.wjgnet.com](http://www.wjgnet.com)

&lt;1%

[全部](#) [新闻](#) [图片](#) [视频](#) [购物](#) [更多 ▾](#) [搜索工具](#)

找到约 76,200 条结果 (用时 1.37 秒)

### Treating hepatocellular carcinoma progression following ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: AR He - 2013 - 被引用次数: 9 - 相关文章

The **Sorafenib HCC** Assessment Randomized Protocol (SHARP) trial, which enrolled 602 ... **HCC** and for whom the **decision** has been made to treat with **sorafenib** under ... on OS to **evaluate the efficacy** of **sorafenib** and other **targeted therapies**. .... agent was **stopped** after one cycle due to progressive disease and **sorafenib** ...

### Potentiality and Boundaries of Use of Sorafenib in Patients ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: M Di Maio - 2012 - 被引用次数: 1 - 相关文章

2012年6月5日 - Keywords: **hepatocellular carcinoma**, **sorafenib**, Child-Pugh B patients, ... Randomized trials documenting the **efficacy** of **sorafenib** were ... the Functional **Assessment** of Cancer **Therapy**-Hepatobiliary Symptom Index 8 questionnaire [6]. .... and 46% of Child B patients **stopped** treatment in the first 8 weeks, ...

### Molecular Targeted Therapies in Hepatocellular Carcinoma

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者: JM Llovet - 2008 - 被引用次数: 788 - 相关文章

**Hepatocellular carcinoma** (HCC) is a complex and heterogeneous tumor with several ... **sorafenib**, Tyrosine kinase inhibitors, phase II, Phase III, trial design, **end-points** ... These results proving the **efficacy** of molecular **targeted therapies** for liver .... Interestingly, patients with activation of RAS/MAPK pathway **assessed** by ...

[全部](#)[图片](#)[视频](#)[地图](#)[新闻](#)[更多 ▾](#)[搜索工具](#)

找到约 33,000 条结果 (用时 0.70 秒)

### Treating hepatocellular carcinoma progression following first-line ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者: AR He - 2013 - 被引用次数: 12 - [相关文章](#)

The **Sorafenib** HCC Assessment Randomized Protocol (SHARP) trial, which enrolled 602 ... HCC and for whom the **decision** has been made to treat with **sorafenib** under ... on OS to **evaluate the efficacy** of **sorafenib** and other **targeted therapies**. .... agent was **stopped** after one cycle due to progressive disease and **sorafenib** ...

### Hepatocellular carcinoma: Will novel targeted drugs really impact the ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者: L Montella - 2016 - 被引用次数: 1

2016年7月21日 - Keywords: **Hepatocellular carcinoma**, **Targeted therapy**, Pathway, Angiogenesis, **Sorafenib** ... Well-designed clinical trials may disclose differences in **efficacy** ... HCC, investigated first-line and second-line treatments but **failed** to detect ... The Prodigy 21 study is investigating **sorafenib** in HCC patients with ...

### Chemotherapy and target therapy for hepatocellular carcinoma: New ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > NCBI > Literature > PubMed Central (PMC) ▾ [翻译此页](#)

作者: GL Deng - 2015 - 被引用次数: 21 - [相关文章](#)

2015年4月18日 - **Hepatocellular carcinoma** (HCC) accounts for 90% of primary liver cancers ... With the advent of **sorafenib**, systemic **therapy** for these patients has ... This palliative chemotherapy was disappointing and **failed** to meet its primary endpoint .... Accordingly, a randomized phase III trial to **evaluate the efficacy** and ...



[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多 ▾](#)[搜索工具](#)

找到约 72,600 条结果 (用时 0.87 秒)

小提示: 仅限搜索简体中文结果。您可以在设置中指定搜索语言

### Treating hepatocellular carcinoma progression following first-line ...

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者: AR He - 2013 - 被引用次数: 12 - 相关文章

The Sorafenib HCC Assessment Randomized Protocol (SHARP) trial, which enrolled 602 ... HCC and for whom the decision has been made to treat with sorafenib under ... on OS to evaluate the efficacy of sorafenib and other targeted therapies. .... agent was stopped after one cycle due to progressive disease and sorafenib....

### Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide ...

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) > NCBI > Literature > PubMed Central (PMC) ▾ [翻译此页](#)

作者: AH Køstner - 2013 - 被引用次数: 14 - 相关文章

2013年1月29日 - In this study we evaluate the efficacy and tolerability of sorafenib in an ... benefit complicates treatment evaluation and clinical decision making [7]. ... for treatment response to targeted therapies in advanced HCC [7, 8]. .... Only three patients (4%) stopped sorafenib therapy due to a specific adverse event.

### Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the ...

[theoncologist.alphamedpress.org/content/15/suppl\\_4/42.long](http://theoncologist.alphamedpress.org/content/15/suppl_4/42.long) ▾ [翻译此页](#)

作者: R Lencioni - 2010 - 被引用次数: 109 - 相关文章

Sorafenib is the first targeted agent to lead to better outcomes in patients with .... The trial was stopped early at the ninth assessment because of a significant .... Currently, phase I and phase II studies are under way to evaluate the efficacy of this .... in patients with HCC who are unsuitable for or have failed curative therapy.